BACKGROUND: MicroRNAs (miRNA, miR) are noncoding RNAs that regulate gene expression by hindering translation. miRNA expression profiles have been shown to differ in vivo and in vitro in many cellular processes associated with cardiovascular diseases (CVDs). The progression of CVDs has also been shown to alter the blood miRNA profile in humans.
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According to the WHO, cardiovascular diseases (CVDs) 3 of atherosclerotic origin are the leading cause of death globally, accounting for 26.8% of deaths among men and for 31.5% among women. The occurrence of atherosclerosis begins to increase among middle-aged people. Autopsy studies have also shown that Ͼ80% of young adults who have died due to noncardiac causes had a more than 25% stenosis in at least one of their main coronary arteries (1 ) . Almost half of all patients suffer a major cardiovascular event, i.e., myocardial infarction or stroke, without a prior diagnosis of CVD. Sudden cardiac arrest accounts for 10% of total mortality and 40% of mortality from coronary heart disease. There are several patient characteristics and demographic and lifestyle factors, as well as clinical conditions, that are known risk factors for sudden cardiac arrest, but their combined predictive value is low. The addition of several lipid-related markers or their combinations to statistical models containing classical risk factors have led to only slight improvement in CVD prediction (2 ) . Therefore, the recognition of high-risk cardiovascular patients remains one of the major unsolved problems in clinical practice.
MicroRNAs (miRNAs, miRs) are small [approximately 18 -24 nucleotides (nt)] noncoding regulatory RNAs. They inversely regulate their target gene expression at the posttranscriptional level by inhibiting translation or causing degradation of the target messenger RNA (mRNA). The 18th release of the MicroRNA Database predicts that Homo sapiens may have 1527 miRNA precursors and 1921 mature miRNAs. The discrepancy between the number of mature miRNAs and precursors results from the fact that one miRNA precursor hairpin can be processed into several miRNAs (-3p and -5p or, for example, miR-21 and miR-21*). On the other hand, several distinct precursor miRNAs can be processed to form the same sequence, i.e., one mature miRNA. The number of predicted miRNAs in humans has increased steadily since the discovery of the molecules in humans in the early 21st century. It has also been predicted that the expression of more than one-third of human genes is regulated by one or more miRNAs, and the number of target genes is increasing in line with the discovery of novel miRNAs.
miRNAs are thought to be micromanagers of the expression of individual genes and biological pathways. Different cell types have different miRNA expression profiles, ranging from miRNAs expressed in most cell types to those that are preferably or even exclusively expressed in specific cell types. miRNAs have a crucial role in the development of animals, regulating the formation of tissues and organs (3 ) . In addition, different pathological disease states have been shown to have identifiable miRNA profiles. Therefore, miRNA profiles could be used as diagnostic and prognostic markers for several diseases. This is possible because, unlike mRNAs, miRNAs are not rapidly degraded in plasma or other body fluids and can thus be detected reliably. They also may become useful in disease treatment because miRNA levels can be modified.
There are many good reviews describing the effects of miRNAs on cholesterol metabolism and human cardiac diseases. The rationale of the present review is to focus on the roles of miRNAs in the development of atherosclerotic lesions and in the changes that atherosclerosis may induce in the miRNA profile of different blood fractions. The present information originates from research done with cell cultures, mice, and humans, with special emphasis on the results obtained in studies using human samples. Our aim was also to elucidate the roles of these miRNAs, often connected to atherosclerosis only through in vivo and in vitro experiments, by relating their expression levels in situ to advanced atherosclerotic plaques and histologically healthy arterial tissue by using Tampere Vascular Study (TVS) data (4 ).
Atherosclerosis
Atherosclerosis is a systemic disease affecting the whole arterial tree of the human body. It can lead to multiplesite vascular disease (polyvascular disease) in the form of coronary artery, peripheral arterial, and cerebrovascular disease. Although cardiovascular deaths are caused by events in different areas of the arterial tree, a large proportion of them are caused by coronary artery disease (CAD). In addition to intravascular features, many systemic factors contribute to the risk of acute coronary events. Although atherosclerosis was at one time considered to be a lipid storage disease, subsequent research has shown that inflammatory cells, innate immunity, and inflammation play central roles in all stages of atherosclerotic disease from the early initial lesion to the late-stage plaque rupture (5 ).
The normal artery consists of 3 layers from the inner to the outer wall: the intima, media, and adventitia. Fatty streaks and lesions are found primarily in large and medium-sized muscular arteries in areas where the blood flow is turbulent or the velocity of the blood flow is decreased, leading to decreased levels of shear stress. The level of shear stress affects gene expression, signaling cascades, and cytokine secretion. Decreased endothelial shear stress also increases the intake, production, and oxidation of LDL in the fatty streaks of the arterial wall (6 ) . Oxidized LDL (oxLDL) is cytotoxic, giving rise to a local inflammatory process which leads to the chronic inflammation observed in atherosclerosis and activation of endothelial cells. This inflammatory process increases the expression of adhesion molecules and infiltration of leukocytes. In the intima monocytes mature into macrophages, which engulf modified lipoproteins via receptor-mediated endocytosis. Subsequently, as a result of the accumulation of cholesterol, the macrophages transform into foam cells. As the fatty streaks progress into atherosclerotic lesions, an increased population of vascular smooth muscle cells (VSMCs) can be found in the thickened intima, underneath the layer of macrophages and foam cells. Activated VSMCs also produce components of the extracellular matrix involved in the evolution of the lipid-rich fatty streak into a more advanced fibrotic lesion. When the amount of extracellular lipids increases and a well-defined fibrous cap is formed, the lesion has developed into an atheroma.
The fibrous cap has an important role in maintaining the mechanical stability of the plaque. Steady growth of a stable atherosclerotic plaque usually does not lead to acute events until the stenosis becomes hemodynamically important. In most cases, end-organ ischemia and infarctions are caused by physical disruption of the lesion's fibrous cap, leading to release of thrombogenic constituents of the plaque and to the formation of a thrombus, which can block the blood flow in the artery. Alterations of the plaque surface (fissures and ulcerations) can show large variations between advanced atherosclerotic plaques (7 ) . Studies have shown that plaque rupture is not a rare event in the progression of atherosclerosis and that only roughly 11% of discovered plaque ruptures are new, whereas most have been preceded by earlier, undiscovered ruptures.
Activated macrophages and T cells are frequently found at the site of the rupture. Inflammatory cells destabilize the plaque by secreting proinflammatory cytokines, proteases, coagulation factors, and vasoactive molecules (5 ) . These molecules inhibit the formation of a stable fibrous cap, degrade the collagen in the cap, and initiate the formation of the clot. The stability of the plaque is also influenced by the cellular growth rate, apoptosis, and lipid metabolism of the vascular wall.
miRNA Biogenesis, Functions, and Transportation between Cells miRNA BIOGENESIS miRNAs are transcribed from the genome of the cell. The majority of mammalian miRNA genes are located in defined transcription units, and their expression is regulated by promoter areas similar to those found in protein-coding genes. Other miRNAs have been found in the introns and even exons of protein-coding genes (8 ) . The expression of intragenic miRNAs is mostly regulated by the promoter of the host gene, which leads to similar expression patterns for the miRNA and the mRNA. Host gene-independent expression regulation of intragenic miRNAs has also been reported (9 ) . The intergenic miRNAs have promoters of their own, which have the characteristics commonly associated with RNA polymerase II-mediated transcription. Clustered miRNAs share one promoter and are coregulated and transcribed as a long primary miRNA transcript (10 ) . Most mammalian miRNAs are transcribed by RNA polymerase II, but some miRNAs, associated with short interspersed nuclear elements, and those originating from viruses are transcribed by RNA polymerase III.
Most miRNAs are transcribed as part of longer primary miRNA transcripts (pri-miRNAs) that are several kilobases long and capped, spliced, and polyadenylated. In such pri-miRNAs, the miRNA sequences form stem-loop structures (or hairpins). These stemloop structures are recognized by a multiprotein complex with Drosha and Di George syndrome critical region gene region 8 (DGCR8). The DGCR8 binds the double-stranded RNA, and the RNase III enzyme Drosha cleaves the double-stranded stem approximately 11 bp from the base of the stem and leaves a 2-nt overhang at the 3Ј end. The formed 70 -100-bp-long RNA molecule is called precursor miRNA (premiRNA) (10 ). Another, rare biogenesis pathway has been indicated for miRNAs derived from introns (mintrons) that are similar in size as the premiRNAs to begin with and do not have to be processed by Drosha. The spliceosome splices mintrons out of the host gene transcripts to form looped intermediates (lariant), which then refold into the pre-miRNA structure ( Fig.  1) (11 ) .
Pre-miRNAs are recognized by the Exportin 5 protein and exported out of the nucleus through the nuclear pore complex in a RanGTP-dependent process. There, the pre-miRNAs are further processed by another RNase III enzyme, Dicer. This enzyme recognizes the 3Ј overhang of the pre-miRNA, binds it with its PAZ (Piwi, Argonaute, and Zwille) domain, and cleaves it into the mature miRNA. The processed miRNA is composed of double-stranded RNA overhangs with lengths of 22 bp and 2 nt on both ends. These mature miRNAs are incorporated into RNAinduced silencing complexes (RISC). While this complex assembles, the miRNA duplex is unwound by helicase and the passenger strand (miRNA*) is degraded, leaving the guide strand within the miRISC. Analysis has shown that the strand with less stable base pair binding in its 5Ј end is more often selected as a guide strand. It has been suggested that the Dicer is repositioned after the cleavage reaction and, in its new position, the helicase domain in Dicer senses the thermodynamic stability of the ends and incorporates the guide strand into the RISC (forming miRISC) (12 ) .
FUNCTION OF miRNAS, miRNA TRANSPORTATION, AND SIGNALING BETWEEN CELLS AND TISSUES
The guide strand of the miRNA leads the miRISC to a partially complementary target mRNA. This complex binds to the target sequence that is more commonly located within the 3Ј untranslated region (UTR) of the mRNA (10 ) . Functional miRNA target sequences in 5Ј UTR and in the open reading frame have also been reported (13 ) . The seed region of the miRNA (the first 2-8 nt) is especially important for miRNA target recognition. Target prediction programs use these seed sequences to predict the mRNA targets for miRNAs, but the existence of a seed region binding sequence in mRNA does not guarantee miRNA binding or translational repression. Furthermore, due to the short seed region, single miRNAs have been predicted to bind hundreds of mRNAs, and individual mRNAs can also be bound by several miRNAs.
Different levels of complementarity between the miRNA and mRNA can lead to various effects on gene expression. If the complementarity is perfect, miRNA functions as a short interfering RNA (siRNA), and the target mRNA is sequence-specifically cleaved by the miRISC complex. This is rare in mammals, and most miRNAs bind their target with partial complementarity, leaving bulges in the formed double-stranded molecule (miRNA-mRNA). The bulges hinder the cleavage function of the miRISC, and this kind of binding leads to the repression of translation and degradation of the mRNA via deadenylation (10 ) . The repression of translation has been hypothesized to be caused by the miRISC's interactions with the initiation of translation and by the steric hindrance of the translating ribosomes. The partially complementary binding of the miRISC can also lead to the recruitment of deadenylase complexes and to the removal or shortening of the poly(A) tail of the mRNA. The shortening or complete removal of the poly(A) tail induces the removal of miRNAs can be produced via different pathways, depending on whether the short RNA is coded in its own gene or in the introns or exons of protein coding genes. miRNAs coded by their own genes are transcribed as long pri-miRNAs, which are polyadenylated and 5Ј-capped. This molecule is then cleaved to shorter pre-miRNAs by Drosha. miRNAs coded in protein coding genes can be processed from the mRNA in a Drosha-independent process, but a hairpinlike pre-miRNA is again formed. The pre-miRNA is then exported from the nucleus to the cytoplasm, where it is cleaved by Dicer to form the mature miRNA duplex. This double-stranded RNA molecule is incorporated into the RISC. The passenger strand of the miRNA is removed and degraded during the incorporation. The single-stranded (guide strand) miRNA guides the miRISC complex to the mRNA target with adequate sequence complementarity, and the binding of miRISC to the mRNA leads to degradation of the mRNA or repression of translation through static hindrance. miRNAs can also be relocated to the nucleus, where they may regulate transcription, or they can be secreted from the cell via, e.g., exosomes, microvesicles, autosomal bodies, and lipoproteins. PRO, promoter; E1, exon 1; E2, exon 2; Ago2, Argonaute 2; NPM1, nucleophosmin 1.
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miRNAs have also been suggested to have other roles in the cells, including functioning as translational activators (14 ) and possibly as transcriptional regulators. Some miRNAs have a nuclear localization sequence and are mainly located in the nucleus instead of the cytoplasm, where they could regulate gene transcription (15 ) . miRNAs have also been localized to mitochondria, possibly regulating mitochondrial gene expression.
miRNAs can be transported between cells and tissues. Both membrane-free miRNAs and miRNAs associated with vesicles can be found in the blood. The nonvesicle-associated miRNAs are thought to be stabilized by protein complexes, such as the RISC proteins Argonaute 2 (16 ) and nucleophosmin 1 (17 ) . The release mechanism of these miRNAs is unclear, but they may have been freed to the blood stream as a consequence of a passive release of the cell content in necrosis. Membrane-bound miRNAs have been found in apoptotic bodies, exosomes, and microvesicles. The packing of the miRNAs in these vesicles can be random, but a regulated method has also been suggestedfor example, Zernecke et al. have shown that certain miRNAs are enriched in apoptotic bodies (18 ) . miR-143/145-enriched vesicles have been shown to convey atheroprotective signaling from endothelial cells to VSMCs (19 ) . Circulating miRNAs have also been found in HDL particles. Cellular export of miRNAs to HDL has been shown to be regulated by neutral sphingomyelinase, and the delivery to receiving cells has been demonstrated to be dependent on scavenger receptor class B type I (20 ) . Circulating miRNAs have been reported to be involved in cell-to-cell communication and, potentially, to have a role in disease progression (18 ) .
miRNAs in Cardiovascular System Development and Vascular Biology miRNAS IN CARDIOVASCULAR SYSTEM DEVELOPMENT
miRNAs are necessary for the proper development of the cardiovascular system. Dicer-deficient mice die during midgestation between E12.5 and E14.5. These embryos have severely compromised vascular development/maintenance in both the embryo and the yolk sack. More specifically, the deletion of Dicer expression in embryonic VSMCs leads to lethality and excessive bleeding. Furthermore, mouse embryos with cardiacspecific Dicer deletion die during gestation. These embryos exhibit pericardial edema and a poorly developed ventricular myocardium. In more detail, the miRNAs let-7f, miR-27b, -221, -222, -145, -143, -21, and the miR-17-92 cluster have been connected to the development of the vasculature. Similarly, miR-1, -133, -208a, -208b, and -499 have been shown to have a role in myocardial development. A detailed review of miRNAs in the development of the cardiovascular system has been provided by Boettger et al. (21 ) .
miRNAS IN ARTERY WALL CELLS, CIRCULATING LEUKOCYTES, PERIPHERAL BLOOD FRACTIONS, AND ATHEROSCLEROTIC

LESIONS
Endothelial cells. miR-21 has been shown to be upregulated in endothelial cells in response to shear stress (22 ) , and miR-10a expression is decreased in atherosclerosis-prone areas (23 ) . The expression of miR-155 has been thought to protect the endothelium by decreasing the expression of endothelin-1 and angiotensin II type I receptor (24 ) . miR-126 has been shown to be specifically expressed in the endothelial cells, where it seems to modulate the phenotype of these cells and, particularly, the response to migration induced by vascular endothelial growth factor and fibroblast growth factor 2 (25 ). Interestingly, miR-126 has also been shown to regulate the expression of vascular cell adhesion molecule 1, an adhesion molecule that mediates leukocyte-endothelial cell adhesion in the arterial endothelium (26 ) . In addition, apoptotic endothelial cells in atherosclerotic lesions have been shown to release miR-126 -enriched apoptotic bodies, which cause other endothelial cells to attract endothelial progenitor cells to the site, to hinder lesion development (18 ) . In an atherosclerotic artery, miR-34a is thought to have a role in the apoptosis and senescence of endothelial cells (27 ) , whereas the expression of miR-210 is induced by the hypoxia in the plaque and causes increased tubulogenesis of endothelial cells as well as possible neovascularization (28 ) . Hypoxia has been demonstrated to increase lesion progression in atherosclerosis by promoting lipid accumulation, inflammation, and ATP depletion, and the neovascularization following the hypoxic state has been connected to rupture-prone plaques (Fig. 2) . CVDs have been shown to alter the miRNA expression profile in the serum, plasma, platelets, and peripheral blood mononuclear cells. Many cellular processes related to atherosclerosis also lead to dysregulation of miRNAs. Specific changes in miRNA profiles can be seen in the differentiation of T cells and of monocytes to macrophages, as well as in foam cell formation. Atherosclerosis activates endothelial cells and drives VSMCs through a phenotypic change, processes which also alter the expression of miRNAs. In addition to research on cellular processes, atherosclerosis has been shown to upregulate some and downregulate other miRNAs in human arteries. The arrows after the miRNA indicate whether it has been up or downregulated.
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Review -146a (32 ), -208 (36 ), and -26a (37 ) have been connected to the synthetic phenotype of VSMCs mainly functioning in platelet-derived growth factor signaling and the cell cycle. In contrast, miR-1 (38 ), -133 (39 ),  -10a (40 ), -21 (30, 41 ) , -143, -145 (42 ), -100 (43 ),  -204 (44 ) , and let-7d (45 ) expression has been associated with the contractile VSMCs (Fig. 2) , where they have been connected to the inhibition of cell proliferation and migration and promotion of contractility.
Leukocytes: lymphocytes, dendritic cells, and monocytes.
The multiple roles of leukocytes in the development of atherosclerosis are thought to be regulated by miRNAs. 
immunodeficient (53 ). miRNA-155 is also needed for the survival of regulatory T cells and for the T-helper 17 response (54 ). miRNAs may also affect T-cell function in atherosclerosis by regulating antigen-presenting cells-for example, dendritic cells. miR-155 and -146a in particular have been hypothesized to have an important role in dendritic cell function and activation (55 ).
The differentiation of monocytes to macrophages results in changes in the miRNA expression profile (Fig. 2) . miRNA-17-5p, miR-20a, and miR-106a expression decreases, allowing their target Runt-related transcription factor 1 to be upregulated, which leads to increased colony stimulating factor receptor expression and monocyte differentiation (56 ) . In the differentiation process, the expression of miR-21 (57 ) and miR-146 (58 ) increases. The polarization of macrophages has also been shown to alter miRNA profiles. The activation of macrophages (towards the M1 and/or M2 phenotype) was shown by Graff et al. to increase the expression of miR-125a, -193b, -27a*, -155*, and -29b-1* and to decrease the expression of miR-26a*. Interestingly, the expression of miR-222* was increased in M2 macrophages and decreased in M1 macrophages in their study (59 ) . In contrast, Zhang et al. found miR-181a, -155-5p, -204-5p, and -451 to be significantly upregulated and miR-125-5p, -146a, 143-3p, and -145-5p to be significantly downregulated when these investigators compared murine M1 macrophages to M2 macrophages (60 ) . When the differentiated macrophages are treated with oxLDL to stimulate foam cell formation, miR-146a, -146b-5p, -155, -9, and -125a-5p expressions are upregulated (61 ) . Of these upregulated miRNAs, miR-155 functions as a negative feedback regulator, decreasing the inflammatory response and lipid uptake through scavenger receptors (62 ) . In contrast to Chen et al. (62 ) , Yang et al. found miR-146a to be significantly downregulated in oxLDLstimulated macrophages. They also found this miRNA to have very similar functions as miR-155 after the stimulation, mainly decreasing cytokine production and lipid uptake (63 ) . The results regarding miR-155 in macrophages, foam cells, and even in murine atherosclerotic plaques are conflicting. Both pro-and antiinflammatory effects have been reported (64, 65 ) . Recent studies indicate that the oxidization level of LDL engulfed by macrophages may affect the changes of miR-155 expression (65 ) and that even in mice the level of dyslipidemia may determine whether this miRNA functions as an anti-or proatherogenic molecule (64 ) .
Circulating miRNAs. Atherosclerosis may also exert an effect on the expression of miRNAs in the peripheral blood of the patients. miRNAs have been profiled from the erythrocytes, platelets, serum, and plasma, and the miRNA profiles of individuals with and without CVD have been shown to differ from each other (66 ) . shows that miRNAs also can be transported by lipoproteins and that familial hyperlipidemia can alter this profile. Their findings also indicated that other lipoproteins besides HDL, such as LDL, may also facilitate miRNA transport (20 ) , thereby making the whole lipoprotein system a part of the miRNA signaling system, mediating its effects between different cells and tissues via the blood and/or extracellular fluids. miRNAs in the atherosclerotic plaque: a summary of the expression of the vascular biology-associated miRNAs discussed in this review in atherosclerotic plaques found in the TVS. The miRNA expression profile has not been studied extensively in situ. The miRNA expression profile of carotid neointimal lesions in rats has been described. In this animal study, comparison of a neointimal lesion to a healthy artery showed that miR-21 is the most upregulated miRNA (30 ) . Furthermore, Li et al., while studying the expression of 13 preselected miRNAs, observed increased expression of miR-21, -130a, -27b, -210, and let-7f in the intimal layer of arterial plaques from patients with atherosclerosis. These investigators also showed a parallel upregulation of miR130a, miR-27b, and miR-210 in the serum of patients with atherosclerosis (73 ) . The upregulation of miR30e-5p, -26b, and -125a, and the downregulation of miR-520b and miR-105 have also been reported in carotid plaques in comparison to nonatherosclerotic left internal thoracic arteries (LITA) (74 ), and Cipollone et al. found that, from a preselected pool of 41 miRNAs, miR-100, -127, -133a, -133b, and -145 were significantly upregulated in symptomatic carotid plaques when compared to asymptomatic plaques (75 ) .
We have previously published the miRNA expression profiles of human atherosclerotic plaques from peripheral arteries (carotid, femoral, and abdominal aorta) in comparison to LITAs (4 ). We found that miR-21, -34a, -146a, -146b-5p, and -210 were the most upregulated miRNAs in atherosclerotic plaques in comparison to LITAs. We also found several predicted targets of these miRNAs to be downregulated in plaques, connecting them to the morphology, phenotype, and proliferation of VSMC as well as HDL and LDL metabolism.
Further utilizing our miRNA profiling from the peripheral atherosclerotic plaques in comparison to healthy LITAs, we have analyzed the expressions of the miRNAs presented in this review (Table 1) . This analysis shows that several miRNAs previously found to be expressed differently in the blood fractions of CAD patients vs non-CAD individuals also demonstrate similar expression differences in atherosclerotic plaques in at least one vascular bed compared with a healthy arterial wall (miR-126, -134, -145, -146a, -198, -210 , -340*, and -92a). Moreover, several miRNAs that have been connected to atherosclerosis by cell culture experiments have been found to be expressed in a similar pattern in the plaque, as predicted by these experiments. For example, those miRNAs that have been shown to have an increased expression in the development of monocytes to macrophages and foam cells were often upregulated in the plaque (miR-146a, -146b-5p, -155, -21), and several miRNAs indicated in the contractive phenotype of VSMCs were also downregulated (miR-10a, -133, -145), whereas those connected to the secreting phenotype were upregulated in the plaque tissue compared with healthy arteries (miR146a, -21, -221) . The complexity of the atherosclerotic plaque composition and formation process and the multiple roles of miRNAs in tissue may partly explain why this kind of clear connection cannot be seen with all the miRNAs.
The functions as well as cell-and tissue-specific expression sites of all the miRNAs that have been discussed in this review are summarized and related to their expressions in atherosclerotic plaques from different arterial beds as determined in the TVS (Table 1 ) (4 ). This information may provide a more systematic insight into the function of miRNAs in human atherosclerotic lesions.
Clinical Implications
miRNA profiling can provide additional information about the biological processes involved in atherosclerosis, but miRNAs have also been thought to be potential biomarkers and drug targets. Circulating miRNAs have many qualities that make them attractive candidate molecular biomarkers. They are stable and evolutionarily conserved, and the changes in their expression are often tissue or disease specific. They are found in many body fluids such as urine, plasma, serum, and cerebrospinal fluid. Quantitative PCR assays can also make miRNA detection sensitive and specific (76 ) . A drawback is that the normalization of miRNA expression has not yet been standardized, and the effects of blood sample collection and the form of the sample (e.g., serum or plasma) on the miRNA profile in the blood fraction must be taken into an account and optimized carefully (67 ) . Moreover, the influences of age, health status, and dynamic changes of the circulating miRNA profile in different individuals have not been studied sufficiently.
Most of the miRNA biomarker research has been conducted in the context of cancer. Currently, several biomarkers for clinical diagnosis have been marketed. Prometheus Laboratories and Rosetta Genomics have launched a laboratory test intended to discover the source of cancer metastasis by its miRNA profile. Asuragen has also developed tests to diagnose pancreatic cancer (77 ) . Efforts to identify miRNAs whose expression in the blood reflects the current status or future progression of atherosclerotic plaques are ongoing, as we reviewed in the circulating miRNA section (20, 66, 68, 72 ) . So far, only the upregulation of miR-146a in the PBMCs of individuals with CAD in comparison to those not suf- In peripheral human atherosclerotic plaque vs healthy left internal thoracic artery.
k miRNA was defined as expressed if it was expressed in at least half of the plaque tissues (n ϭ 18) or healthy arteries (n ϭ 6).
fering from CAD has been replicated, in 2 independent studies (69, 70 ) . miRNAs have also been seen as direct drug targets. The first locked-nucleic-acid-based drug used in the treatment of hepatitis C has entered phase 2 clinical trials (78 ) . Interesting drug targets may be miRNAs related to early endothelial dysfunction, such as miR10a (23 ) and miR-126 (25 ) . It may be possible to stabilize an unstable plaque by affecting the expression of the miRNAs associated with the rupture-prone phenotype (75 ), as Lovren et al. have shown by promoting the contractile phenotype of VSMCs by the overexpression of miR-145 (79 ) .
Major cardiovascular events are currently prevented by the treatment of risk factors. Most importantly, statins have become widely used for lowering LDL concentrations. Statins have been shown to decrease the expression of miR-146a and -146b (70 ) and to increase let-7i (71 ) expression in the PBMCs of CAD patients. More specifically, atorvastatin has been demonstrated to decrease miR-221/222 (80 ) and miR-34a (81 ) in circulating endothelial progenitor cells, whereas pravastatin or rosuvastatin did not have this effect. The divergent effects of different statins on miRNA expression might be related to the suggested pleiotropic effects of statins. Treatment that directly inhibits miR-33a/b expression has been shown to raise plasma HDL and to lower VLDL triglycerides in African green monkeys (82 ) . Altered miRNA profiles have been associated with other CVD risk factors such as hypertension, diabetes, and smoking, but more research is needed to elucidate the clinical potential of these profiles.
Conclusions and Future Perspectives
Processes related to atherosclerosis have been shown to affect the miRNA expression in cell cultures and animal model experiments. Recently, there also has been active research on biomarker miRNAs for CVDs from different blood fractions. Few reports are available concerning the miRNA expression in actual human atherosclerosis, and the function of miRNAs in human atherosclerotic arteries remains largely unknown. We have reviewed miRNA expression studies on different blood fractions and cells closely related to atherosclerosis and elucidated how these miRNAs, predicted to have a role in human atherosclerosis, are expressed in advanced atherosclerotic lesions in comparison with healthy arteries. Many of the miRNAs shown to have altered expression profiles in the blood fractions of individuals with CVD are also dysregulated in the atherosclerotic artery wall. Such information suggests that the expression of these markers may reflect the changes actually taking place in the arterial wall. We also found that many miRNAs connected to atherosclerosis in cell culture studies are also expressed in the plaque in the same fashion as the experiments have predicted. For example, mir-126, -145, -146a, and -210 are expressed similarly in several tissues and cell types related to atherosclerosis, providing evidence for an association with CVDs. As miRNA in atherosclerosis is still a relatively new field of research, the full clinical potential of these small RNAs in the diagnostics and treatment of CVDs remains to be elucidated.
